Your session is about to expire
← Back to Search
ATX-101 for Leiomyosarcoma (ATX-101 Trial)
ATX-101 Trial Summary
This trial is testing a new drug, ATX-101, to see if it's effective in treating two types of cancer, dedifferentiated liposarcoma (LPS) and leiomyosarcoma (LMS). ATX-101 is an IV drug that's thought to work by blocking the interaction of a protein called PCNA with other proteins involved in the stress response. This trial will see if ATX-101 can disrupt these interactions and help treat the cancer.
- Leiomyosarcoma
- Liposarcoma
ATX-101 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 55 Patients • NCT02123134ATX-101 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your disease is either inoperable or has spread to other parts of your body. If your disease can be removed surgically, but the risks of surgery are too high, you may still be eligible.
- Group 1: ATX-101
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has ATX-101 been granted clearance by the Food and Drug Administration?
"Our team at Power assessed the safety of ATX-101 as a 2, due to it being in Phase 2. This means that while there is data available on its safety, no information has been collected yet regarding efficacy."
What qualifications are necessary to be enrolled in this clinical experiment?
"34 individuals aged 18 to 99, with leiomyosarcoma and an ECOG performance status of ≤2 are eligible for this trial. Additionally, they must have received previous systemic treatment within the last 6 months that aligns with the type of sarcoma (LMS: Anthracycline-based chemotherapy or gemcitabine/docetaxel; LPS: No specification as to prior treatment). As safety data on ATX-101 in minors is unavailable, children cannot participate."
Are there any relevant precedents involving ATX-101?
"ATX-101 is currently being studied by 4 active trials; none of these studies have entered Phase 3. South Brisbane, Queensland serves as the focal point for most research involving ATX-101 however it can also be found in 9 other locations around the world."
Are there any age restrictions for participants of this research?
"This research endeavours to include participants aged 18 and above up until 99 years of age."
Are there any available vacancies in this clinical research project?
"The data found on clinicaltrials.gov indicates that this research is still open for enrolment after being initially posted in the early days of November 2022 and recently updated near the end of the month."
How many participants are eligible for involvement in this research endeavor?
"That is correct. The trial, which was initially published on 1st November 2022 and recently revised on 23rd November 2022, is actively recruiting 34 patients from one medical centre as per the details available on clinicaltrials.gov."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Popular Categories
Share this study with friends
Copy Link
Messenger